MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$5,528K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds issue of common stock-...
Stock-based compensation-Lucid D...
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Change in fair value - senior se...
Accounts receivable
Purchase of equipment
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-11,687
-13,909
-16,266
-10,397
Depreciation and amortization expense
224
222
209
220
Stock-based compensation-Lucid Diagnostics2018Equity Plan
1,680
1,402
4,387
-
Stock-based compensation - lucid diagnostics inc. 2018 equity plan
-
-
-
1,135
Stock-based compensation-Pavmed2014Equity Plan
13
9
104
-
Stock-based compensation - pavmed inc. 2014 equity plan
-
-
-
17
Change in fair value - senior secured convertible note
1,040
-1,859
-12,953
-2,341
Debt extinguishment loss - senior secured convertible note
-
-
0
-
Equity issuance cost extinguishment
-
-
-
1,078
Amortization of common stock payment for vendor service agreement
28
29
0
87
Equity issuance cost extinguishment
-
-
-1,078
-
Accounts receivable
399
46
96
177
Prepaid expenses and other current assets
-52
1,247
616
1,225
Accounts payable
-
108
220
-82
Accrued expenses and other current liabilities
243
-519
443
-146
Due to pavmed inc. - operating expenses, employee related costs, msa fee
-
-
-
-4
Due to pavmed inc. - operating expenses, employee related costs, msa fee-Pavmed
0
-9
16
-
Net cash flows used in operating activities
-11,297
-12,101
-12,578
-10,893
Purchase of equipment
21
215
51
28
Purchase of intellectual property from pavmed inc
-
-
0
-
Net cash flows used in investing activities
-21
-215
-51
-28
Proceeds issue of preferred stock
-
-
0
-
Proceeds issue of common stock - registered direct offering, net of fees
-
-
-
0
Proceeds issue of common stock-Registered Direct Offering
16,845
0
14,935
-
Proceeds issue of common stock - confidentially marketed public offering, net of fees
-
-
-
26,997
Proceeds issue of common stock-Confidentially Marketed Public Offering
0
-
43,171
-
Proceeds issue of senior secured convertible notes
0
0
0
0
Payment repayment of senior secured convertible note
-
-
0
-
Proceeds issue of common stock-Atthemarket Offering
0
5,274
274
-
Proceeds issue of common stock at-the-market facility
-
-
-
0
Tax withholdings on equity based compensation
0
17
-
-
Proceeds exercise of stock options
1
20
2
2
Proceeds issue common stock employee stock purchase plan
0
210
0
272
Net cash flows provided by financing activities
16,846
5,487
2
27,130
Net (decrease) increase in cash
5,528
-6,829
-12,627
16,209
Cash, beginning of period
27,876
34,705
47,332
22,358
Cash, end of period
33,404
27,876
34,705
47,332
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds issue of common
stock-Registered Direct Offering
$16,845K
Proceeds exercise of
stock options
$1K
(-92.31%↓ Y/Y)
Net cash flows
provided by financing...
$16,846K
(-47.19%↓ Y/Y)
Net (decrease)
increase in cash
$5,528K
(-36.93%↓ Y/Y)
Canceled cashflow
$11,318K
Stock-based
compensation-Lucid...
$1,680K
Accrued expenses and
other current...
$243K
(159.71%↑ Y/Y)
Depreciation and
amortization expense
$224K
(-49.44%↓ Y/Y)
Prepaid expenses and
other current assets
-$52K
(-105.52%↓ Y/Y)
Amortization of common stock
payment for vendor...
$28K
(-80.95%↓ Y/Y)
Stock-based
compensation-Pavmed2014Equity Plan
$13K
Net cash flows used
in operating...
-$11,297K
(50.91%↑ Y/Y)
Net cash flows used
in investing...
-$21K
(82.20%↑ Y/Y)
Canceled cashflow
$2,240K
Net loss
-$11,687K
(62.72%↑ Y/Y)
Purchase of equipment
$21K
(-82.20%↓ Y/Y)
Change in fair value -
senior secured...
$1,040K
(-86.38%↓ Y/Y)
Accounts receivable
$399K
(21.65%↑ Y/Y)
Buy us a coffee
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (LUCD)